Trial Profile
A randomized, double-blind, placebo-controlled, phase IIB study of the safety and efficacy of OVAREX MabB43.13 [oregovomab] in ovarian cancer patients with an elevated serum CA 125 but without other evidence of disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Oregovomab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 10 Sep 2005 New trial record.